Showing posts with label Trastuzamab. Show all posts
Showing posts with label Trastuzamab. Show all posts
Saturday, March 27, 2010
full access: Trastuzumab (Herceptin) sensitizes ovarian cancer cells to EGFR-targeted therapeutics
In research:
Background: Early studies have demonstrated comparable levels of HER2/ErbB2 expression in both breast and ovarian cancer. Trastuzumab (Herceptin), a therapeutic monoclonal antibody directed against HER2, is FDA-approved for the treatment of both early and late stage breast cancer. However, clinical studies of trastuzumab in epithelial ovarian cancer (EOC) patients have not met the same level of success. Surprisingly, however, no reports have examined either the basis for primary trastuzumab resistance in ovarian cancer or potential ways of salvaging trastuzumab as a potential ovarian cancer therapeutic.
add your opinions
Herceptin
,
Trastuzamab
Subscribe to:
Posts
(
Atom
)